Skip to main content
Erschienen in: Surgical Endoscopy 5/2008

01.05.2008 | Letter

Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer?

verfasst von: Theodore Liakakos, Dimitrios H. Roukos

Erschienen in: Surgical Endoscopy | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Excerpt

The safety and efficacy of laparoscopic gastrectomy has been demonstrated in phase II studies [1] and remain to be confirmed in large-scale phase III clinical trials. There are two potential advantages for performing laparoscopic gastrectomy rather than open gastrectomy: first, it improves quality of life (QOL) and, second, an increase in survival rates. Based on data from laparoscopic colorectal surgery, it is unlikely that laparoscopic gastrectomy may improve survival or cure rates for gastric cancer patients. What is the impact of laparoscopic approach on QOL? …
Literatur
1.
Zurück zum Zitat Lee JH, Kim YW, Ryu KW (2007) A phase-II clinical trial of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer patients. Ann Surg Oncol. Aug 20; [Epub ahead of print] Lee JH, Kim YW, Ryu KW (2007) A phase-II clinical trial of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer patients. Ann Surg Oncol. Aug 20; [Epub ahead of print]
2.
Zurück zum Zitat Shehzad K, Mohiuddin K, Nizami S et al (2007) Current status of minimal access surgery for gastric cancer. Surg Oncol 16(2):85–98. Epub 2007 Jun 7PubMedCrossRef Shehzad K, Mohiuddin K, Nizami S et al (2007) Current status of minimal access surgery for gastric cancer. Surg Oncol 16(2):85–98. Epub 2007 Jun 7PubMedCrossRef
3.
Zurück zum Zitat Yasuda K, Shiraishi N, Etoh T, Shiromizu A, Inomata M, Kitano S (2007) Long-term quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc 21:2150–215PubMedCrossRef Yasuda K, Shiraishi N, Etoh T, Shiromizu A, Inomata M, Kitano S (2007) Long-term quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc 21:2150–215PubMedCrossRef
4.
Zurück zum Zitat Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820PubMedCrossRef Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820PubMedCrossRef
5.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMedCrossRef Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMedCrossRef
6.
Zurück zum Zitat Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgas Couchell S (1990) A critical-evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach—an analysis of early results and long-term survival. J Cancer Res Clin 116(3):307–313CrossRef Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgas Couchell S (1990) A critical-evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach—an analysis of early results and long-term survival. J Cancer Res Clin 116(3):307–313CrossRef
7.
Zurück zum Zitat Siewert JR, Bottcher K, Stein HJ, Roder JD (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228(4):449–461PubMedCrossRef Siewert JR, Bottcher K, Stein HJ, Roder JD (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228(4):449–461PubMedCrossRef
8.
Zurück zum Zitat Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81(2):59–62PubMedCrossRef Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81(2):59–62PubMedCrossRef
9.
Zurück zum Zitat Kappas AM, Fatouros M, Roukos DH (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11(8):727–730PubMedCrossRef Kappas AM, Fatouros M, Roukos DH (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11(8):727–730PubMedCrossRef
10.
Zurück zum Zitat Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol Feb;11(2):127–129CrossRef Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol Feb;11(2):127–129CrossRef
11.
Zurück zum Zitat Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125PubMedCrossRef Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125PubMedCrossRef
12.
Zurück zum Zitat Gervasoni JE, Sbayi S, Cady B (2007) Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol (in press) DOI: 10.1245/s10434-007-9360-5 Gervasoni JE, Sbayi S, Cady B (2007) Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol (in press) DOI: 10.​1245/​s10434-007-9360-5
13.
Zurück zum Zitat Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98–107PubMedCrossRef Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98–107PubMedCrossRef
14.
Zurück zum Zitat Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM (2001) Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 84(12):1602–1609PubMedCrossRef Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM (2001) Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 84(12):1602–1609PubMedCrossRef
15.
Zurück zum Zitat Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 80(1):16–24PubMed Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 80(1):16–24PubMed
16.
Zurück zum Zitat Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7(4):253–255PubMedCrossRef Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7(4):253–255PubMedCrossRef
17.
Zurück zum Zitat Roukos DH (1999) Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 6(1):46–56PubMedCrossRef Roukos DH (1999) Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 6(1):46–56PubMedCrossRef
18.
Zurück zum Zitat Roukos DH, Lorenz M, Encke A (1998) Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 123(5):573–578PubMedCrossRef Roukos DH, Lorenz M, Encke A (1998) Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 123(5):573–578PubMedCrossRef
19.
Zurück zum Zitat Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730PubMedCrossRef Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730PubMedCrossRef
20.
Zurück zum Zitat Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9(3):220–221PubMedCrossRef Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9(3):220–221PubMedCrossRef
21.
Zurück zum Zitat Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14(10):2691–2695PubMedCrossRef Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14(10):2691–2695PubMedCrossRef
22.
Zurück zum Zitat Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6(6):931–939PubMedCrossRef Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6(6):931–939PubMedCrossRef
23.
Zurück zum Zitat Norton JA, Ham CM, Van Dam J et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245(6):873–879PubMedCrossRef Norton JA, Ham CM, Van Dam J et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245(6):873–879PubMedCrossRef
24.
Zurück zum Zitat Chung DC, Yoon SS, Lauwers GY, Patel D (2007) Case records of the Massachusetts General Hospital. Case 22–2007. A woman with a family history of gastric and breast cancer. N Engl J Med 357(3):283–291PubMedCrossRef Chung DC, Yoon SS, Lauwers GY, Patel D (2007) Case records of the Massachusetts General Hospital. Case 22–2007. A woman with a family history of gastric and breast cancer. N Engl J Med 357(3):283–291PubMedCrossRef
25.
Zurück zum Zitat Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6(3):308–312PubMedCrossRef Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6(3):308–312PubMedCrossRef
26.
Zurück zum Zitat Kim JJ, Song KY, Chin HM, Kim W, Jeon HM, Park CH, Park SM (2007) Totally laparoscopic gastrectomy with various types of intracorporeal anastomosis using laparoscopic linear staplers: preliminary experience. Surg Endosc Jun 26; [Epub ahead of print] Kim JJ, Song KY, Chin HM, Kim W, Jeon HM, Park CH, Park SM (2007) Totally laparoscopic gastrectomy with various types of intracorporeal anastomosis using laparoscopic linear staplers: preliminary experience. Surg Endosc Jun 26; [Epub ahead of print]
27.
Zurück zum Zitat Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578–590PubMedCrossRef Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578–590PubMedCrossRef
28.
Zurück zum Zitat Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9(7):607–609PubMedCrossRef Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9(7):607–609PubMedCrossRef
29.
Zurück zum Zitat Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943PubMed Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943PubMed
30.
Zurück zum Zitat Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15:21–33PubMedCrossRef Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15:21–33PubMedCrossRef
31.
Zurück zum Zitat Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11(12):1030–1034PubMedCrossRef Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11(12):1030–1034PubMedCrossRef
32.
Zurück zum Zitat Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:1555–1556PubMedCrossRef Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:1555–1556PubMedCrossRef
33.
Zurück zum Zitat Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10(7):718–721PubMedCrossRef Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10(7):718–721PubMedCrossRef
34.
Zurück zum Zitat Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737–745PubMedCrossRef Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737–745PubMedCrossRef
35.
Zurück zum Zitat Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8(1):29–39PubMedCrossRef Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8(1):29–39PubMedCrossRef
36.
Zurück zum Zitat Liakakos T, Roukos DH (2008) More controversy than ever – challenges and promises towards personlized treatment of gastric cancer. Ann Surg Oncol 15(4):959–960PubMedCrossRef Liakakos T, Roukos DH (2008) More controversy than ever – challenges and promises towards personlized treatment of gastric cancer. Ann Surg Oncol 15(4):959–960PubMedCrossRef
37.
Zurück zum Zitat Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197PubMedCrossRef Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197PubMedCrossRef
38.
Zurück zum Zitat Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141PubMedCrossRef Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141PubMedCrossRef
Metadaten
Titel
Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer?
verfasst von
Theodore Liakakos
Dimitrios H. Roukos
Publikationsdatum
01.05.2008
Verlag
Springer-Verlag
Erschienen in
Surgical Endoscopy / Ausgabe 5/2008
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-008-9890-3

Weitere Artikel der Ausgabe 5/2008

Surgical Endoscopy 5/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.